Methylphenidate significantly improves driving performance of adults with attention-deficit hyperactivity disorder: a randomized crossover trial
Although patients with attention-deficit hyperactivity disorder (ADHD) have reported improved driving performance on methylphenidate, limited evidence exists to support an effect of treatment on driving performance and some regions prohibit driving on methylphenidate. A randomized, crossover trial e...
Gespeichert in:
| Veröffentlicht in: | Journal of psychopharmacology (Oxford) 2008-05, Vol.22 (3), p.230-237 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 237 |
|---|---|
| container_issue | 3 |
| container_start_page | 230 |
| container_title | Journal of psychopharmacology (Oxford) |
| container_volume | 22 |
| creator | Verster, Joris C Bekker, Evelijne M de Roos, Marlise Minova, Anita Eijken, Erik JE Kooij, JJ Sandra Buitelaar, Jan K. Kenemans, J Leon Verbaten, Marinus N. Olivier, Berend Volkerts, Edmund R |
| description | Although patients with attention-deficit hyperactivity disorder (ADHD) have reported improved driving performance on methylphenidate, limited evidence exists to support an effect of treatment on driving performance and some regions prohibit driving on methylphenidate. A randomized, crossover trial examining the effects of methylphenidate versus placebo on highway driving in 18 adults with ADHD was carried out. After three days of no treatment, patients received either their usual methylphenidate dose (mean: 14.7 mg; range: 10—30 mg) or placebo and then the opposite treatment after a six to seven days washout period. Patients performed a 100 km driving test during normal traffic, 1.5 h after treatment administration. Standard deviation of lateral position (SDLP), the weaving of the car, was the primary outcome measure. Secondary outcome measurements included the standard deviation of speed and patient reports of driving performance. Driving performance was significantly better in the methylphenidate than in the placebo condition, as reflected by the SDLP difference (2.3 cm, 95% CI = 0.8—3.8, P = 0.004). Variation in speed was similar on treatment and on placebo (-0.05 km/h, 95% CI = -0.4 to 0.2, P = 0.70). Among adults with ADHD, with a history of a positive clinical response to methylphenidate, methylphenidate significantly improves driving performance. |
| doi_str_mv | 10.1177/0269881107082946 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_746273771</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A180223517</galeid><sage_id>10.1177_0269881107082946</sage_id><sourcerecordid>A180223517</sourcerecordid><originalsourceid>FETCH-LOGICAL-c505t-cfca4017f0354a77bef1ff5c1a66be654503e4115955fe7b71239c56d992ff633</originalsourceid><addsrcrecordid>eNp9kl1rFDEUhgdR7LZ675UEwXo1Ncnka3pXil9Q8Uavh2xyspsyk6xJpjL-Cn-yWXexUFByEch53vPmfDTNC4IvCJHyLaaiV4oQLLGiPROPmhVhgrSSKv64We3D7T5-0pzmfIsxEUzwp80JUR1WUqlV8-szlO0y7rYQvNUFUPab4J03OpRxQX7apXgHGdnk73zYoB0kF9OkgwEUHdJ2HktGP3zZIl0KhOJjaC3UBL6g7VJxbUqVlgVZn2OykC6RRkkHGyf_EywyKeZcPRIqyevxWfPE6THD8-N91nx7_-7r9cf25suHT9dXN63hmJfWOKMZJtLhjjMt5RoccY4booVYg-CM4w4YIbzn3IFcS0K73nBh-546J7rurHlzyFsL_D5DLsPks4Fx1AHinAfJBJWdlKSS5_8lRd9hqXpRwVcPwNs4p1CrGGi1Z5hRWqGLA7TRIww-uFhqi-qxMHkTQ21dfb8iCleYE1kF-CD406gEbtglP-m0DAQP-y0YHm5Blbw8fmReT2DvBcexV-D1EdDZ6NHVcRif_3IU19YStvduD1zWG7iv5p_GvwHfyclc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>212340422</pqid></control><display><type>article</type><title>Methylphenidate significantly improves driving performance of adults with attention-deficit hyperactivity disorder: a randomized crossover trial</title><source>MEDLINE</source><source>SAGE Journals</source><creator>Verster, Joris C ; Bekker, Evelijne M ; de Roos, Marlise ; Minova, Anita ; Eijken, Erik JE ; Kooij, JJ Sandra ; Buitelaar, Jan K. ; Kenemans, J Leon ; Verbaten, Marinus N. ; Olivier, Berend ; Volkerts, Edmund R</creator><creatorcontrib>Verster, Joris C ; Bekker, Evelijne M ; de Roos, Marlise ; Minova, Anita ; Eijken, Erik JE ; Kooij, JJ Sandra ; Buitelaar, Jan K. ; Kenemans, J Leon ; Verbaten, Marinus N. ; Olivier, Berend ; Volkerts, Edmund R</creatorcontrib><description>Although patients with attention-deficit hyperactivity disorder (ADHD) have reported improved driving performance on methylphenidate, limited evidence exists to support an effect of treatment on driving performance and some regions prohibit driving on methylphenidate. A randomized, crossover trial examining the effects of methylphenidate versus placebo on highway driving in 18 adults with ADHD was carried out. After three days of no treatment, patients received either their usual methylphenidate dose (mean: 14.7 mg; range: 10—30 mg) or placebo and then the opposite treatment after a six to seven days washout period. Patients performed a 100 km driving test during normal traffic, 1.5 h after treatment administration. Standard deviation of lateral position (SDLP), the weaving of the car, was the primary outcome measure. Secondary outcome measurements included the standard deviation of speed and patient reports of driving performance. Driving performance was significantly better in the methylphenidate than in the placebo condition, as reflected by the SDLP difference (2.3 cm, 95% CI = 0.8—3.8, P = 0.004). Variation in speed was similar on treatment and on placebo (-0.05 km/h, 95% CI = -0.4 to 0.2, P = 0.70). Among adults with ADHD, with a history of a positive clinical response to methylphenidate, methylphenidate significantly improves driving performance.</description><identifier>ISSN: 0269-8811</identifier><identifier>EISSN: 1461-7285</identifier><identifier>DOI: 10.1177/0269881107082946</identifier><identifier>PMID: 18308788</identifier><identifier>CODEN: JOPSEQ</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Adult ; Attention deficit hyperactivity disorder ; Automobile driving ; Automobile Driving - psychology ; Biological and medical sciences ; Central Nervous System Stimulants - therapeutic use ; Clinical trials ; Cross-Over Studies ; Dosage and administration ; Double-Blind Method ; Drug therapy ; Female ; Health aspects ; Humans ; Male ; Medical sciences ; Methylphenidate ; Methylphenidate - therapeutic use ; Methylphenidate hydrochloride ; Middle Aged ; Motor vehicle driving ; Neuropharmacology ; Pharmacology. Drug treatments ; Psychiatric Status Rating Scales ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer ; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) ; Psychology. Psychoanalysis. Psychiatry ; Psychomotor Performance - drug effects ; Psychopharmacology ; Regression Analysis ; Stimulants ; Treatment Outcome</subject><ispartof>Journal of psychopharmacology (Oxford), 2008-05, Vol.22 (3), p.230-237</ispartof><rights>2008 INIST-CNRS</rights><rights>COPYRIGHT 2008 Sage Publications Ltd. (UK)</rights><rights>Copyright Sage Publications Ltd. May 2008</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c505t-cfca4017f0354a77bef1ff5c1a66be654503e4115955fe7b71239c56d992ff633</citedby><cites>FETCH-LOGICAL-c505t-cfca4017f0354a77bef1ff5c1a66be654503e4115955fe7b71239c56d992ff633</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/0269881107082946$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/0269881107082946$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21819,27924,27925,43621,43622</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20401147$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18308788$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Verster, Joris C</creatorcontrib><creatorcontrib>Bekker, Evelijne M</creatorcontrib><creatorcontrib>de Roos, Marlise</creatorcontrib><creatorcontrib>Minova, Anita</creatorcontrib><creatorcontrib>Eijken, Erik JE</creatorcontrib><creatorcontrib>Kooij, JJ Sandra</creatorcontrib><creatorcontrib>Buitelaar, Jan K.</creatorcontrib><creatorcontrib>Kenemans, J Leon</creatorcontrib><creatorcontrib>Verbaten, Marinus N.</creatorcontrib><creatorcontrib>Olivier, Berend</creatorcontrib><creatorcontrib>Volkerts, Edmund R</creatorcontrib><title>Methylphenidate significantly improves driving performance of adults with attention-deficit hyperactivity disorder: a randomized crossover trial</title><title>Journal of psychopharmacology (Oxford)</title><addtitle>J Psychopharmacol</addtitle><description>Although patients with attention-deficit hyperactivity disorder (ADHD) have reported improved driving performance on methylphenidate, limited evidence exists to support an effect of treatment on driving performance and some regions prohibit driving on methylphenidate. A randomized, crossover trial examining the effects of methylphenidate versus placebo on highway driving in 18 adults with ADHD was carried out. After three days of no treatment, patients received either their usual methylphenidate dose (mean: 14.7 mg; range: 10—30 mg) or placebo and then the opposite treatment after a six to seven days washout period. Patients performed a 100 km driving test during normal traffic, 1.5 h after treatment administration. Standard deviation of lateral position (SDLP), the weaving of the car, was the primary outcome measure. Secondary outcome measurements included the standard deviation of speed and patient reports of driving performance. Driving performance was significantly better in the methylphenidate than in the placebo condition, as reflected by the SDLP difference (2.3 cm, 95% CI = 0.8—3.8, P = 0.004). Variation in speed was similar on treatment and on placebo (-0.05 km/h, 95% CI = -0.4 to 0.2, P = 0.70). Among adults with ADHD, with a history of a positive clinical response to methylphenidate, methylphenidate significantly improves driving performance.</description><subject>Adult</subject><subject>Attention deficit hyperactivity disorder</subject><subject>Automobile driving</subject><subject>Automobile Driving - psychology</subject><subject>Biological and medical sciences</subject><subject>Central Nervous System Stimulants - therapeutic use</subject><subject>Clinical trials</subject><subject>Cross-Over Studies</subject><subject>Dosage and administration</subject><subject>Double-Blind Method</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Methylphenidate</subject><subject>Methylphenidate - therapeutic use</subject><subject>Methylphenidate hydrochloride</subject><subject>Middle Aged</subject><subject>Motor vehicle driving</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Psychiatric Status Rating Scales</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</subject><subject>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychomotor Performance - drug effects</subject><subject>Psychopharmacology</subject><subject>Regression Analysis</subject><subject>Stimulants</subject><subject>Treatment Outcome</subject><issn>0269-8811</issn><issn>1461-7285</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kl1rFDEUhgdR7LZ675UEwXo1Ncnka3pXil9Q8Uavh2xyspsyk6xJpjL-Cn-yWXexUFByEch53vPmfDTNC4IvCJHyLaaiV4oQLLGiPROPmhVhgrSSKv64We3D7T5-0pzmfIsxEUzwp80JUR1WUqlV8-szlO0y7rYQvNUFUPab4J03OpRxQX7apXgHGdnk73zYoB0kF9OkgwEUHdJ2HktGP3zZIl0KhOJjaC3UBL6g7VJxbUqVlgVZn2OykC6RRkkHGyf_EywyKeZcPRIqyevxWfPE6THD8-N91nx7_-7r9cf25suHT9dXN63hmJfWOKMZJtLhjjMt5RoccY4booVYg-CM4w4YIbzn3IFcS0K73nBh-546J7rurHlzyFsL_D5DLsPks4Fx1AHinAfJBJWdlKSS5_8lRd9hqXpRwVcPwNs4p1CrGGi1Z5hRWqGLA7TRIww-uFhqi-qxMHkTQ21dfb8iCleYE1kF-CD406gEbtglP-m0DAQP-y0YHm5Blbw8fmReT2DvBcexV-D1EdDZ6NHVcRif_3IU19YStvduD1zWG7iv5p_GvwHfyclc</recordid><startdate>20080501</startdate><enddate>20080501</enddate><creator>Verster, Joris C</creator><creator>Bekker, Evelijne M</creator><creator>de Roos, Marlise</creator><creator>Minova, Anita</creator><creator>Eijken, Erik JE</creator><creator>Kooij, JJ Sandra</creator><creator>Buitelaar, Jan K.</creator><creator>Kenemans, J Leon</creator><creator>Verbaten, Marinus N.</creator><creator>Olivier, Berend</creator><creator>Volkerts, Edmund R</creator><general>SAGE Publications</general><general>Sage</general><general>Sage Publications Ltd. (UK)</general><general>Sage Publications Ltd</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>20080501</creationdate><title>Methylphenidate significantly improves driving performance of adults with attention-deficit hyperactivity disorder: a randomized crossover trial</title><author>Verster, Joris C ; Bekker, Evelijne M ; de Roos, Marlise ; Minova, Anita ; Eijken, Erik JE ; Kooij, JJ Sandra ; Buitelaar, Jan K. ; Kenemans, J Leon ; Verbaten, Marinus N. ; Olivier, Berend ; Volkerts, Edmund R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c505t-cfca4017f0354a77bef1ff5c1a66be654503e4115955fe7b71239c56d992ff633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Attention deficit hyperactivity disorder</topic><topic>Automobile driving</topic><topic>Automobile Driving - psychology</topic><topic>Biological and medical sciences</topic><topic>Central Nervous System Stimulants - therapeutic use</topic><topic>Clinical trials</topic><topic>Cross-Over Studies</topic><topic>Dosage and administration</topic><topic>Double-Blind Method</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Methylphenidate</topic><topic>Methylphenidate - therapeutic use</topic><topic>Methylphenidate hydrochloride</topic><topic>Middle Aged</topic><topic>Motor vehicle driving</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Psychiatric Status Rating Scales</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer</topic><topic>Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychomotor Performance - drug effects</topic><topic>Psychopharmacology</topic><topic>Regression Analysis</topic><topic>Stimulants</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Verster, Joris C</creatorcontrib><creatorcontrib>Bekker, Evelijne M</creatorcontrib><creatorcontrib>de Roos, Marlise</creatorcontrib><creatorcontrib>Minova, Anita</creatorcontrib><creatorcontrib>Eijken, Erik JE</creatorcontrib><creatorcontrib>Kooij, JJ Sandra</creatorcontrib><creatorcontrib>Buitelaar, Jan K.</creatorcontrib><creatorcontrib>Kenemans, J Leon</creatorcontrib><creatorcontrib>Verbaten, Marinus N.</creatorcontrib><creatorcontrib>Olivier, Berend</creatorcontrib><creatorcontrib>Volkerts, Edmund R</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of psychopharmacology (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Verster, Joris C</au><au>Bekker, Evelijne M</au><au>de Roos, Marlise</au><au>Minova, Anita</au><au>Eijken, Erik JE</au><au>Kooij, JJ Sandra</au><au>Buitelaar, Jan K.</au><au>Kenemans, J Leon</au><au>Verbaten, Marinus N.</au><au>Olivier, Berend</au><au>Volkerts, Edmund R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Methylphenidate significantly improves driving performance of adults with attention-deficit hyperactivity disorder: a randomized crossover trial</atitle><jtitle>Journal of psychopharmacology (Oxford)</jtitle><addtitle>J Psychopharmacol</addtitle><date>2008-05-01</date><risdate>2008</risdate><volume>22</volume><issue>3</issue><spage>230</spage><epage>237</epage><pages>230-237</pages><issn>0269-8811</issn><eissn>1461-7285</eissn><coden>JOPSEQ</coden><abstract>Although patients with attention-deficit hyperactivity disorder (ADHD) have reported improved driving performance on methylphenidate, limited evidence exists to support an effect of treatment on driving performance and some regions prohibit driving on methylphenidate. A randomized, crossover trial examining the effects of methylphenidate versus placebo on highway driving in 18 adults with ADHD was carried out. After three days of no treatment, patients received either their usual methylphenidate dose (mean: 14.7 mg; range: 10—30 mg) or placebo and then the opposite treatment after a six to seven days washout period. Patients performed a 100 km driving test during normal traffic, 1.5 h after treatment administration. Standard deviation of lateral position (SDLP), the weaving of the car, was the primary outcome measure. Secondary outcome measurements included the standard deviation of speed and patient reports of driving performance. Driving performance was significantly better in the methylphenidate than in the placebo condition, as reflected by the SDLP difference (2.3 cm, 95% CI = 0.8—3.8, P = 0.004). Variation in speed was similar on treatment and on placebo (-0.05 km/h, 95% CI = -0.4 to 0.2, P = 0.70). Among adults with ADHD, with a history of a positive clinical response to methylphenidate, methylphenidate significantly improves driving performance.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>18308788</pmid><doi>10.1177/0269881107082946</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-8811 |
| ispartof | Journal of psychopharmacology (Oxford), 2008-05, Vol.22 (3), p.230-237 |
| issn | 0269-8811 1461-7285 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_746273771 |
| source | MEDLINE; SAGE Journals |
| subjects | Adult Attention deficit hyperactivity disorder Automobile driving Automobile Driving - psychology Biological and medical sciences Central Nervous System Stimulants - therapeutic use Clinical trials Cross-Over Studies Dosage and administration Double-Blind Method Drug therapy Female Health aspects Humans Male Medical sciences Methylphenidate Methylphenidate - therapeutic use Methylphenidate hydrochloride Middle Aged Motor vehicle driving Neuropharmacology Pharmacology. Drug treatments Psychiatric Status Rating Scales Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease) Psychology. Psychoanalysis. Psychiatry Psychomotor Performance - drug effects Psychopharmacology Regression Analysis Stimulants Treatment Outcome |
| title | Methylphenidate significantly improves driving performance of adults with attention-deficit hyperactivity disorder: a randomized crossover trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T07%3A35%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Methylphenidate%20significantly%20improves%20driving%20performance%20of%20adults%20with%20attention-deficit%20hyperactivity%20disorder:%20a%20randomized%20crossover%20trial&rft.jtitle=Journal%20of%20psychopharmacology%20(Oxford)&rft.au=Verster,%20Joris%20C&rft.date=2008-05-01&rft.volume=22&rft.issue=3&rft.spage=230&rft.epage=237&rft.pages=230-237&rft.issn=0269-8811&rft.eissn=1461-7285&rft.coden=JOPSEQ&rft_id=info:doi/10.1177/0269881107082946&rft_dat=%3Cgale_proqu%3EA180223517%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=212340422&rft_id=info:pmid/18308788&rft_galeid=A180223517&rft_sage_id=10.1177_0269881107082946&rfr_iscdi=true |